<DOC>
	<DOCNO>NCT00960713</DOCNO>
	<brief_summary>The primary purpose study describe prospective observational study serious adverse event occur patient treat off-label rituximab various auto-immune disease .</brief_summary>
	<brief_title>The RITAI Cohort : An Observational Study Rituximab Off-label Use Auto-immune Disorders</brief_title>
	<detailed_description>Every patient treat rituximab -label auto-immune disease public hospital Midi-Pyrénées County ( France ) eligible study , whatever dose number plan infusion . The enrollment definitive time first rituximab infusion begin . Follow-up visit plan month 1 , 3 , 6 , 12 18 first infusion . At visit , investigator record adverse event occur since last visit . Serious unexpected adverse event systematically monitor declared Pharmacovigilance . Imputability quote accord French method . A biological collection constitute allow pharmaco- immunological study .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 18 year rituximab prescribe offlabel autoimmune disorder rituximab prescription validate institutional board Patients give informed consent include cohort Followup 6 month presumably doubtful Rituximab prescribe rheumatoïd arthritis Rituximab prescribe lymphoma Pregnant breath feed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>observational cohort</keyword>
	<keyword>rituximab</keyword>
	<keyword>off-label use</keyword>
	<keyword>auto-immunity</keyword>
	<keyword>cytopenia</keyword>
</DOC>